iCAD (ICAD) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Achieved 21% year-over-year revenue growth in Q2 2024, reaching $5.0 million, driven by expanded sales, upgrades, and cloud transitions.
Completed transformation plan phases, including divesting Xoft, stabilizing cash burn, and launching SaaS/cloud growth initiatives.
Gross margin improved to 84% in Q2 2024 from 81% in Q2 2023, reflecting higher software license revenue and operational efficiency.
Net loss from continuing operations narrowed to $1.7 million ($0.07/share) in Q2 2024 from $2.3 million ($0.09/share) in Q2 2023.
Profound Cloud SaaS platform launch exceeded expectations, supporting a more predictable revenue model.
Financial highlights
Q2 2024 revenue was $5.0 million, up 21% year-over-year; six-month revenue was $10.0 million, up 17%.
Q2 2024 gross profit was $4.2 million (84% margin); six-month gross profit was $8.3 million (83% margin).
Adjusted EBITDA loss improved to $1.2 million from $2.1 million year-over-year.
Cash and equivalents were $20.4 million as of June 30, 2024; net working capital was $21.1 million.
Net cash used in operations improved 43% year-over-year; $1.1 million used in the first half of 2024.
Outlook and guidance
SaaS/cloud transition expected to drive long-term profitability and cash flow, though near-term GAAP revenue may be impacted by ratable recognition.
Management expects continued growth in recurring revenue as cloud and subscription models expand.
Liquidity is sufficient to sustain operations for at least the next 12 months.
Recurring revenue base (ARR) provides increasing visibility and predictability for future quarters.
Cloud adoption anticipated to outpace subscription growth, with strong early indicators.
Latest events from iCAD
- Q3 2024 revenue up 4% to $4.2M, ARR at $9.3M, and FDA clearance boosts future growth.ICAD
Q3 2024 - Cloud-based AI and strategic partnerships drive growth in mammography diagnostics.ICAD
17th Annual LD Micro Main Event Conference - $103M all-stock deal unites AI breast imaging leaders, boosting growth and global reach.ICAD
Status Update - Q1 2025 saw stable revenue, improved margins, and a pending RadNet acquisition.ICAD
Q1 2025 - Double-digit revenue and ARR growth driven by SaaS, cloud, and new AI product launch.ICAD
Q4 2024